Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2023-07-13 AGM Information
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
112年年報及股東會資料 — 2023_1734_20230620FE3.pdf
AGM Information Classification · 95% confidence The document is titled 'Sinphar Pharmaceutical Co., Ltd. 2023 Shareholders’ Meeting Minutes' and contains detailed minutes of a shareholders' meeting held on June 20, 2023. It includes attendance details, chairperson remarks, company reports, ratifications of the 2022 Business Report and Financial Statements, voting results, and resolutions. The document also contains the 2022 Business Report with operational performance, financial and profitability analysis, research and development activities, and business plans for 2023. The content is comprehensive and includes substantive financial data and management discussion. This is consistent with materials typically presented and approved at an Annual General Meeting (AGM). The document is not merely an announcement or a brief summary but a full record of the AGM proceedings including financial reports and shareholder votes. Therefore, the document fits best under the category AGM Information (AGM-R).
2023-07-13 Chinese
112年年報及股東會資料 — 2023_1734_20230620F05.pdf
AGM Information Classification · 100% confidence The document is a detailed record of the Annual General Meeting (AGM) of 杏輝藥品工業股份有限公司 for the year 112 (2023). It includes the meeting date, attendance, agenda items, reports presented, approval of the previous year's business report and financial statements, dividend distribution, and other shareholder resolutions. The document also contains voting results for each agenda item and attachments such as the business report, audit committee report, and financial statements. The content is typical of AGM minutes, which document the proceedings and decisions made during the annual shareholders meeting. It is not merely an announcement or a presentation but the official meeting minutes with detailed voting outcomes and reports referenced as attachments. Therefore, the appropriate classification is AGM Information (AGM-R).
2023-07-13 Chinese
112年年報及股東會資料 — 2022_1734_20230620FE4.pdf
Annual Report Classification · 98% confidence The document contains extensive sections typical of a comprehensive yearly report, including a Letter to Shareholders, Business Report, Company Profile, Corporate Governance Report, Company Shares and Fundraising, Operational Highlights, Financial Information with multiple years of data, Audit Committee's Review Report, Consolidated Financial Statements, and detailed analysis of financial status, performance, and risk. The presence of audited financial statements and detailed business and financial analysis strongly indicates this is a full Annual Report. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a certification. Therefore, the document is classified as an Annual Report (10-K).
2023-07-13 Chinese
112年年報及股東會資料 — 2023_1734_20230620F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains a detailed table listing the top ten shareholders of the company 杏輝藥品工業股份有限公司, including their shareholdings, relationships among shareholders, and related notes. This type of information is typical of a Major Shareholding Notification, which reports changes or details about significant share ownership levels. The document is short (1508 characters) and does not contain financial statements or other report content, so it is not an Annual Report or Interim Report. It is not an announcement of voting results, board changes, or other categories. Therefore, the best fit is Major Shareholding Notification (MRQ).
2023-07-13 Chinese
112年年報及股東會資料 — 2022_1734_20230620F04.pdf
Annual Report Classification · 100% confidence The document is titled as an annual report for 杏輝藥品工業股份有限公司, containing detailed sections such as a letter to shareholders, business report for the fiscal year 111 (which corresponds to a full fiscal year), company overview, governance report, capital and financing details, operational overview, and comprehensive financial data including audited financial statements. The length is substantial (15,000 characters), and it includes detailed financial performance, business strategy, R&D progress, and governance information. This matches the characteristics of a full Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a summary; it contains substantive financial and operational data for the year. Therefore, the correct classification is Annual Report (10-K).
2023-07-13 Chinese
112年年報及股東會資料 — 2023_1734_20230620FE2.pdf
AGM Information Classification · 95% confidence The document is a detailed agenda and materials for the 2023 Annual Shareholders' Meeting of Sinphar Pharmaceutical Co., Ltd. It includes meeting procedures, agenda items such as company reports, ratifications, discussions, and extraordinary motions. It also contains attachments like the 2022 Business Report, Audit Committee’s Review Report, 2022 Financial Statements, and amendments to board meeting rules. The presence of detailed business reports, financial statements, and audit committee reviews within the document indicates it is the actual meeting materials rather than just an announcement. The document is comprehensive and exceeds 5,000 characters, containing substantive financial data and company reports. This aligns with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2023-07-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.